Medincell Presents Its Strategy at the Biopharma Symposium 2025
Medincell, a biopharmaceutical licensing company, will participate in the Truist Securities Biopharma Symposium 2025 in New York to discuss its strategy, advancements, and outlook.
According to the press release, Medincell, a biopharmaceutical company based in Montpellier, will take part in the Truist Securities Biopharma Symposium 2025 in New York on November 6, 2025. Dr. Grace Kim, Chief Strategy Officer, U.S. Finance, will present the company's strategy, recent advancements, and development prospects. Attendees will also have the opportunity to arrange meetings with Medincell's management team.
Innovative Drug Delivery Technology
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Medincell develops long-acting injectable drugs using its proprietary BEPO® technology. This system allows for the release of a drug at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection. The first treatment using this technology, aimed at schizophrenia, was approved by the FDA in April 2023 and is marketed in the United States under the name UZEDY® by Teva Pharmaceuticals.
Extensive Drug Development Portfolio
Medincell's portfolio includes several drug candidates in development, ranging from formulation to phase 3 clinical trials. The company collaborates with leading pharmaceutical companies and foundations to offer new treatment options aimed at improving global health. Currently, Medincell employs over 140 people from 25 different nationalities.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
